Literature DB >> 33807895

Cerebral Cavernous Malformation 1 Determines YAP/TAZ Signaling-Dependent Metastatic Hallmarks of Prostate Cancer Cells.

Sangryong Park1, Ho-Young Lee1,2, Jayoung Kim3, Hansol Park4, Young Seok Ju4, Eung-Gook Kim5, Jaehong Kim1,2.   

Abstract

Enhanced Yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ) signaling is correlated with the extraprostatic extension of prostate cancer. However, the mechanism by which YAP/TAZ signaling becomes hyperactive and drives prostate cancer progression is currently unclear. In this study, we revealed that higher expression of CCM1, which is uniquely found in advanced prostate cancer, is inversely correlated with metastasis-free and overall survival in patients with prostate cancer. We also demonstrated that CCM1 induces the metastasis of multiple types of prostate cancer cells by regulating YAP/TAZ signaling. Mechanistically, CCM1, a gene mutated in cerebral cavernous malformation, suppresses DDX5, which regulates the suppression of YAP/TAZ signaling, indicating that CCM1 and DDX5 are novel upstream regulators of YAP/TAZ signaling. Our findings highlight the importance of CCM1-DDX5-YAP/TAZ signaling in the metastasis of prostate cancer cells.

Entities:  

Keywords:  DDX5; YAP/TAZ signaling; cerebral cavernous malformation; metastasis; prostate cancer

Year:  2021        PMID: 33807895      PMCID: PMC7961486          DOI: 10.3390/cancers13051125

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  1 in total

1.  FSCN1 Promotes Glycolysis and Epithelial-Mesenchymal Transition in Prostate Cancer through a YAP/TAZ Signaling Pathway.

Authors:  Minghui Li; Zhiming Gao; Honglin Ding; Zhanhua Wang; Hada Mu; Lei Zhang; Jiufu Wei; Zhanshu Ma
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-29       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.